{"id":"ustekinumab-90-mg","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Upper respiratory tract infection"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Injection site reaction"}]},"_chembl":{"chemblId":"CHEMBL1201835","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the p40 subunit, ustekinumab prevents the formation of the IL-12 and IL-23 heterodimers, which are key cytokines involved in the inflammatory response. This leads to a decrease in the production of pro-inflammatory cytokines and a reduction in inflammation. Ustekinumab is used to treat various inflammatory conditions, including psoriasis, psoriatic arthritis, and Crohn's disease.","oneSentence":"Ustekinumab is a monoclonal antibody that targets and binds to the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby inhibiting their activity and reducing inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:39.159Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Moderate to severe Crohn's disease"}]},"trialDetails":[{"nctId":"NCT06045754","phase":"PHASE4","title":"A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-04-18","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT07444060","phase":"","title":"Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"CD - Crohn's Disease, Stricture; Bowel, IBD - Inflammatory Bowel Disease","enrollment":100},{"nctId":"NCT05387031","phase":"","title":"Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-08-01","conditions":"Crohn Disease, Stricture; Bowel, Intestinal Stricture","enrollment":239},{"nctId":"NCT06520397","phase":"PHASE4","title":"Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-07-15","conditions":"Crohn Disease","enrollment":214},{"nctId":"NCT07245394","phase":"","title":"Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)","status":"RECRUITING","sponsor":"TIDHI Innovation Inc.","startDate":"2026-01-29","conditions":"Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)","enrollment":200},{"nctId":"NCT07303686","phase":"PHASE4","title":"De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2025-10-08","conditions":"Crohn Disease (CD), Ulcerative Colitis (UC)","enrollment":115},{"nctId":"NCT07263464","phase":"","title":"The Association Between TNFSF4 Polymorphism and CD","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2018-01-01","conditions":"Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Polymorphism, Single Nucleotide, Ustekinumab","enrollment":818},{"nctId":"NCT05029921","phase":"PHASE4","title":"A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-12-10","conditions":"Crohn Disease","enrollment":182},{"nctId":"NCT07177118","phase":"PHASE3","title":"Risankizumab for Fibrostenotic Crohn's Disease Treatment","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10-20","conditions":"Crohn Disease, Crohn Disease and Ulcerative Colitis","enrollment":260},{"nctId":"NCT05335356","phase":"PHASE3","title":"Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Biocon Biologics UK Ltd","startDate":"2022-06-28","conditions":"Moderate to Severe Chronic Plaque Psoriasis","enrollment":384},{"nctId":"NCT02648581","phase":"PHASE2","title":"Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-14","conditions":"Behçet Disease","enrollment":16},{"nctId":"NCT04978493","phase":"PHASE2","title":"A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2021-12-02","conditions":"Crohn Disease","enrollment":49},{"nctId":"NCT07149467","phase":"PHASE3","title":"Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-09-10","conditions":"Crohn's Disease Aggravated, Crohn's Disease in Remission","enrollment":454},{"nctId":"NCT03358706","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-02","conditions":"Crohn Disease, Ulcerative Colitis","enrollment":28},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":"Crohn Disease","enrollment":297},{"nctId":"NCT06997055","phase":"","title":"ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar","status":"RECRUITING","sponsor":"Celltrion HealthCare France","startDate":"2025-03-17","conditions":"Crohn Disease, Plaque Psoriasis","enrollment":225},{"nctId":"NCT06453317","phase":"PHASE2","title":"Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Medical University of Lodz","startDate":"2025-02-17","conditions":"Ulcerative Colitis, Inflammatory Bowel Diseases","enrollment":172},{"nctId":"NCT03981744","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments","status":"TERMINATED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2019-07-26","conditions":"Polymyositis, Dermatomyositis","enrollment":51},{"nctId":"NCT03782376","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2018-12-20","conditions":"Crohn Disease","enrollment":215},{"nctId":"NCT03517722","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-16","conditions":"Lupus Erythematosus, Systemic","enrollment":516},{"nctId":"NCT02438787","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-31","conditions":"Axial Spondyloarthritis","enrollment":315},{"nctId":"NCT02877134","phase":"PHASE2","title":"Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08-25","conditions":"Crohn Disease","enrollment":388},{"nctId":"NCT03464136","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2018-03-29","conditions":"Crohn Disease","enrollment":386},{"nctId":"NCT02437162","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-03","conditions":"Axial Spondyloarthritis","enrollment":347},{"nctId":"NCT04882072","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)","status":"TERMINATED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-09-15","conditions":"Takayasu Arteritis","enrollment":14},{"nctId":"NCT02407236","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-10","conditions":"Colitis, Ulcerative, Inflammatory Bowel Diseases","enrollment":961},{"nctId":"NCT03107793","phase":"PHASE3","title":"Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2017-04-19","conditions":"Crohn Disease","enrollment":500},{"nctId":"NCT02968108","phase":"PHASE1","title":"A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-01-18","conditions":"Crohn Disease","enrollment":45},{"nctId":"NCT06935942","phase":"","title":"The Associations of Plasminogen Activator Inhibitor-1 Gene Polymorphisms With Crohn's Disease in Chinese Patients","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-01-01","conditions":"Crohn Disease","enrollment":906},{"nctId":"NCT06935929","phase":"","title":"A Study on the Associations Between Microribonucleic Acid Gene Polymorphisms and Crohn's Disease","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-01-01","conditions":"Crohn Disease","enrollment":839},{"nctId":"NCT03885713","phase":"PHASE4","title":"Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2019-09-10","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":180},{"nctId":"NCT05299931","phase":"PHASE3","title":"An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients with Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW","startDate":"2021-09-10","conditions":"Crohn Disease","enrollment":108},{"nctId":"NCT02319759","phase":"PHASE2","title":"Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-03-27","conditions":"Psoriatic Arthritis","enrollment":149},{"nctId":"NCT01369355","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-09-13","conditions":"Crohn's Disease, Colitis, IBD","enrollment":1282},{"nctId":"NCT04060888","phase":"PHASE3","title":"A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2020-07-14","conditions":"Lupus Erythematosus, Systemic","enrollment":""},{"nctId":"NCT03362736","phase":"","title":"An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease","status":"NO_LONGER_AVAILABLE","sponsor":"Janssen Research & Development, LLC","startDate":"","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT06786507","phase":"","title":"A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Helwan University","startDate":"2025-05-15","conditions":"Ulcerative Colitis (UC)","enrollment":100},{"nctId":"NCT03926130","phase":"PHASE3","title":"A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-07-23","conditions":"Crohn's Disease","enrollment":1158},{"nctId":"NCT04607980","phase":"PHASE3","title":"A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-11-11","conditions":"Plaque Psoriasis","enrollment":563},{"nctId":"NCT05169593","phase":"PHASE4","title":"Prevention of Postoperative Endoscopic Recurrence with Endoscopy-driven Versus Systematic Biological Therapy","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2022-09-08","conditions":"Crohn Disease","enrollment":292},{"nctId":"NCT03366142","phase":"PHASE1, PHASE2","title":"Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-02","conditions":"LAD1","enrollment":6},{"nctId":"NCT03711448","phase":"PHASE2","title":"Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2019-01-07","conditions":"Patients Relapsing Refractory Giant Cell Arteritis","enrollment":38},{"nctId":"NCT04245215","phase":"PHASE3","title":"Loss of RESponse to Ustekinumab Treated by Dose Escalation","status":"COMPLETED","sponsor":"Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW","startDate":"2020-03-11","conditions":"Crohn Disease","enrollment":108},{"nctId":"NCT04093531","phase":"PHASE1","title":"Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2020-01-15","conditions":"Primary Sjögren Syndrome","enrollment":12},{"nctId":"NCT06391996","phase":"","title":"Biologic Therapy for Generalized Pustular Psoriasis","status":"COMPLETED","sponsor":"Chao Ji","startDate":"2019-07-01","conditions":"Generalized Pustular Psoriasis","enrollment":65},{"nctId":"NCT01704534","phase":"PHASE2","title":"A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2012-05","conditions":"Hidradenitis Suppurativa","enrollment":20},{"nctId":"NCT03847272","phase":"PHASE2","title":"A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU)","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2019-08-01","conditions":"Patients With Newly Diagnosed Active NISU","enrollment":15},{"nctId":"NCT04261010","phase":"NA","title":"TNF and IL23 Blocking Agents Gene Expression Ratios in the Psoriatic Arthritis Synovium_(TIGERS) Study","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2020-01-14","conditions":"Psoriatic Arthritis","enrollment":36},{"nctId":"NCT04117932","phase":"PHASE2","title":"Efficacy and Safety of Ustekinumab in Bullous Pemphigoid","status":"COMPLETED","sponsor":"CHU de Reims","startDate":"2020-03-11","conditions":"Bullous Pemphigoid","enrollment":18},{"nctId":"NCT04728360","phase":"PHASE3","title":"Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2021-07-06","conditions":"Plaque Psoriasis","enrollment":556},{"nctId":"NCT05705856","phase":"","title":"Effectiveness and Safety of Ustekinumab Intensification in Crohn's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-02-15","conditions":"Crohn Disease","enrollment":200},{"nctId":"NCT05720221","phase":"","title":"Biologics in Management of Inflammatory Bowel Disease in Egyptian Patients","status":"COMPLETED","sponsor":"Helwan University","startDate":"2021-07-15","conditions":"IBD","enrollment":100},{"nctId":"NCT02698475","phase":"PHASE3","title":"An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05","conditions":"Psoriasis","enrollment":44},{"nctId":"NCT02684357","phase":"PHASE3","title":"BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03","conditions":"Psoriasis","enrollment":577},{"nctId":"NCT02684370","phase":"PHASE3","title":"BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02","conditions":"Psoriasis","enrollment":560},{"nctId":"NCT02199496","phase":"PHASE1, PHASE2","title":"Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-10-19","conditions":"Gastrointestinal Inflammation Associated With CVID, CVID Enteropathy","enrollment":5},{"nctId":"NCT02561806","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-10","conditions":"Plaque Psoriasis","enrollment":302},{"nctId":"NCT02955147","phase":"PHASE1, PHASE2","title":"Ustekinumab for the Treatment of Giant Cell Arteritis","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2016-12-01","conditions":"Giant Cell Arteritis, Temporal Arteritis, Horton's Disease","enrollment":13},{"nctId":"NCT02349061","phase":"PHASE2","title":"A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-15","conditions":"Lupus Erythematosus, Systemic","enrollment":102},{"nctId":"NCT01713400","phase":"PHASE2","title":"Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-02-25","conditions":"Graft vs. Host Disease","enrollment":54},{"nctId":"NCT01708603","phase":"PHASE3","title":"P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2012-08","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":1831},{"nctId":"NCT01708629","phase":"PHASE3","title":"Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2012-09","conditions":"Plaque Psoriasis","enrollment":1881},{"nctId":"NCT02826603","phase":"PHASE3","title":"Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-22","conditions":"Plaque Psoriasis","enrollment":1114},{"nctId":"NCT02407223","phase":"PHASE3","title":"An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-13","conditions":"Nonradiographic Axial Spondylitis, Ankylosing","enrollment":356},{"nctId":"NCT01999868","phase":"PHASE2","title":"Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-03-19","conditions":"Psoriasis","enrollment":108},{"nctId":"NCT02203032","phase":"PHASE3","title":"A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-10-07","conditions":"Psoriasis","enrollment":872},{"nctId":"NCT02074982","phase":"PHASE3","title":"Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-02-26","conditions":"Chronic Plaque Type Psoriasis","enrollment":676},{"nctId":"NCT01550744","phase":"PHASE3","title":"A Study of Ustekinumab to Evaluate a \"Subject-tailored\" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2012-03","conditions":"Psoriasis","enrollment":478},{"nctId":"NCT01090063","phase":"NA","title":"Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis","status":"COMPLETED","sponsor":"Tufts Medical Center","startDate":"2010-02","conditions":"Moderate to Severe Palmar Plantar Psoriasis","enrollment":26},{"nctId":"NCT01389973","phase":"PHASE2","title":"A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-09","conditions":"Primary Biliary Cirrhosis","enrollment":20},{"nctId":"NCT01645280","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-08","conditions":"Arthritis, Rheumatoid","enrollment":274},{"nctId":"NCT02156375","phase":"PHASE1","title":"A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-05","conditions":"Healthy","enrollment":140},{"nctId":"NCT01945086","phase":"PHASE2","title":"A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2013-09","conditions":"Dermatitis, Atopic","enrollment":79},{"nctId":"NCT00320216","phase":"PHASE2","title":"A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2003-11","conditions":"Psoriasis","enrollment":320},{"nctId":"NCT01009086","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-12","conditions":"Arthritis, Psoriatic","enrollment":615},{"nctId":"NCT01090427","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-05","conditions":"Psoriasis","enrollment":110},{"nctId":"NCT01276847","phase":"PHASE1","title":"A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03","conditions":"Psoriasis","enrollment":40},{"nctId":"NCT01059773","phase":"PHASE4","title":"A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2009-10","conditions":"Psoriasis","enrollment":490},{"nctId":"NCT00955279","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2009-11","conditions":"Sarcoidosis","enrollment":173},{"nctId":"NCT01081704","phase":"PHASE1","title":"A Study of the Pharmacokinetics of Ustekinumab in Chinese Male Subjects","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2009-10","conditions":"Healthy","enrollment":24},{"nctId":"NCT00723528","phase":"PHASE3","title":"An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-03","conditions":"Psoriasis","enrollment":158},{"nctId":"NCT01077362","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-03","conditions":"Arthritis, Psoriatic","enrollment":312},{"nctId":"NCT00265122","phase":"PHASE2","title":"A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2004-04","conditions":"Crohn Disease","enrollment":131},{"nctId":"NCT00267969","phase":"PHASE3","title":"A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Centocor Research & Development, Inc.","startDate":"2005-12","conditions":"Psoriasis","enrollment":766},{"nctId":"NCT00267956","phase":"PHASE2","title":"An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2005-12","conditions":"Psoriatic Arthritis","enrollment":146},{"nctId":"NCT01330901","phase":"PHASE2","title":"Ustekinumab for the Treatment of Patients With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2011-10","conditions":"Ankylosing Spondylitis","enrollment":22},{"nctId":"NCT00771667","phase":"PHASE2","title":"A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2008-12","conditions":"Crohn's Disease","enrollment":526},{"nctId":"NCT00307437","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Centocor Research & Development, Inc.","startDate":"2005-05","conditions":"Psoriasis","enrollment":1230},{"nctId":"NCT00454584","phase":"PHASE3","title":"An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2007-03","conditions":"Psoriasis","enrollment":903}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABDOMINAL PAIN"},{"count":1,"reaction":"ABSCESS"},{"count":1,"reaction":"CHILLS"},{"count":1,"reaction":"CROHN^S DISEASE"},{"count":1,"reaction":"FISTULA"},{"count":1,"reaction":"MALAISE"},{"count":1,"reaction":"NAUSEA"},{"count":1,"reaction":"PERFORATION"}],"_approvalHistory":[],"publicationCount":83,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Stelara","CNTO 1275","STELARA"],"phase":"phase_3","status":"active","brandName":"Ustekinumab (90 mg)","genericName":"Ustekinumab (90 mg)","companyName":"Janssen Scientific Affairs, LLC","companyId":"janssen-scientific-affairs-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Ustekinumab is a monoclonal antibody that targets and binds to the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby inhibiting their activity and reducing inflammation. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis, Moderate to severe Crohn's disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}